According to the World Health Organization estimates that cancer caused 9.6 million deaths in 2018 and is the second-highest cause of death worldwide. About 1 in 6 fatalities worldwide are caused by cancer. Over the following two decades, there will likely be a 70 percent increase in new cases. Additionally, recent developments have made it possible to overcome this barrier and facilitate the clinical use of RNAi-based therapeutics for cancer treatment.
Data Bridge Market Research analyses that the RNAi therapeutics market which was USD 807.99 million in 2022, would rocket up to USD 1645.76 million by 2030, and is expected to undergo a CAGR of 9.3% during the forecast period 2023 to 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Download the PDF Sample Report (Including FULL TOC, Graphs, and Tables) of this report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=glo...
COVID-19 Impact on RNAi Therapeutics Market
COVID-19 pandemic has positively impacted the market due to the growing relevance of RNA-based investigations and increasing funding for R&D activities. Numerous businesses are investing resources to test diseases that have undergone constant improvement in genomic and molecular understanding to take advantage of opportunities fuelling market growth. As an illustration, in August 2020, Pediatrix Medical Group and GeneDx Inc., a division of BioReference Laboratories Inc., reached an agreement to provide cutting-edge, next-generation genomic sequencing to enable the clinical identification of uncommon disorders for newborn intensive care units.
On February 26, 2020, The Brazilian Health Regulatory Agency (ANVISA) approved ONPATTRO for treating hereditary transthyretin-mediated (hATTR) amyloidosis in adults, according to a prominent company's announcement.
In June 2020, OliX Pharmaceuticals and LGC Biosarch Technology agreed to quicken the manufacturing of asymmetric siRNA for treating wet macular degeneration and subretinal fibrosis.
Global RNAi Therapeutics Market Scope
The RNAi therapeutics market is segmented on the basis of molecule type, application, route of administration and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Small Interfering RNAS
Route of Administration
View Detailed [email protected] https://www.databridgemarketresearch.com/reports/global-rnai-therap...
Research and Academic Laboratories
RNAi Therapeutics Market Regional Analysis/Insights
The RNAi therapeutics market is analyzed and market size insights and trends are provided by country, molecule type, application, route of administration and end-user as referenced above.
The countries covered in the RNAi therapeutics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the RNAi therapeutics market due to the growing geriatric population and innovative medical technology adoption.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 due to the rising health awareness among the people and increasing demand for advanced medical technology.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and RNAi Therapeutics Market Share Analysis
The RNAi therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to RNAi therapeutics market.
Some of the major players operating in the RNAi therapeutics market are:
Quark Software Inc. (U.S.)
F. Hoffmann-La Roche Ltd. (Switzerland)
Rexahn Pharmaceuticals, Inc. (U.S.)
Silence Therapeutics (U.K.)
Arbutus Biopharma (U.S.)
Benitec Biopharma (Australia)
GSK plc (U.K.)
OLIX PHARMACEUTICALS, INC. (South Korea)
Alnylam Pharmaceuticals, Inc. (U.S.)
Moderna Inc. (U.S.)
Ionis Pharmaceuticals (U.S.)
The complete Report is available (Including the full TOC, Tables, and Figures, Graphs as well as Chart) @ https://www.databridgemarketresearch.com/toc/?dbmr=global-rnai-ther...
About Data Bridge Market Research:
An absolute way to forecast what future holds is to comprehend the trend today!
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.